New NCCN Imaging Appropriate Use Criteria Resources Help Assure Patients Receive Best Cancer Care Available

New NCCN Imaging Appropriate Use Criteria Compendium provides a single access point for all imaging recommendations within the NCCN Guidelines

FORT WASHINGTON, PA — The National Comprehensive Cancer Network ® ( NCCN ® ) has published the NCCN Imaging Appropriate Use Criteria (NCCN Imaging AUC™) to support clinical decision-making around the use of imaging in patients with cancer, helping to assure needed and useful imaging while potentially saving patients from unneeded or inappropriate imaging.

NCCN Imaging AUC™ are accessible through the new NCCN Imaging Appropriate Use Criteria Compendium ™ ( NCCN Imaging AUC Compendium ™), which provides imaging appropriate use criteria in an easy-to-use, single-source derivative product. The NCCN AUC Compendium™, a web-based user interface, provides a searchable and user-customized display of approved NCCN Imaging AUC™. Complimentary access to the NCCN Imaging AUC Compendium™ is available at the following link until 2017:  NCCN.org/ImagingAUC  

“The launch of the NCCN Imaging AUC furthers our mission to improve the lives of people with cancer,” said Robert W. Carlson, MD, Chief Executive Officer, NCCN. “This easy-to-use resource, based on the unbiased, expert opinion of NCCN Guidelines panel members, enhances clinical decision-making and helps patients receive the very best cancer care possible.”

NCCN Imaging AUC™ include recommendations pertaining to cancer screening, diagnosis, staging, treatment response assessment, follow-up, and surveillance as outlined within the library of NCCN Clinical Practice Guidelines in Oncology ( NCCN Guidelines ® ). NCCN Imaging AUC™ include all imaging procedures recommended in the NCCN Guidelines®, including radiographs, computed tomography (CT) scans, magnetic resonance imaging (MRI), functional nuclear medicine imaging (PET, SPECT), and ultrasound.

NCCN Imaging AUC™ are available for the following cancer types:

  • Acute Lymphoblastic Leukemia
  • Acute Myeloid Leukemia
  • Bladder Cancer
  • Breast Cancer
  • Genetic/Familial High-Risk Assessment: Breast and Ovarian
  • Genetic/Familial High-Risk Assessment: Colorectal
  • Hodgkin Lymphoma
  • Lung Cancer Screening
  • Neuroendocrine Tumors
  • Pancreatic Adenocarcinoma
  • Prostate Cancer
  • Prostate Cancer Early Detection

Additional cancer types will be published in the coming months.

The NCCN Guidelines are the recognized standard for clinical policy in cancer care and are the most thorough and most frequently updated clinical practice guidelines available in any area of medicine. Other NCCN Guidelines derivative products include:

  • The NCCN Drugs & Biologics Compendium ( NCCN Compendium ® ) contains authoritative, scientifically derived information designed to support decision-making about the appropriate use of drugs and biologics in patients with cancer. The NCCN Compendium® is recognized by public and private insurers alike, including CMS and UnitedHealthcare as an authoritative reference for oncology coverage policy. 
  • The NCCN Biomarkers Compendium ® contains information designed to support decision-making around the use of biomarker testing in patients with cancer.  
  • The NCCN Chemotherapy Order Templates ( NCCN Templates ® ) include chemotherapy, immunotherapy, supportive care agents, monitoring parameters, and safety instructions based directly on recommendations within the NCCN Guidelines. Special instructions for self-administered chemotherapeutic agents are also provided.  

For more information and to access the NCCN AUC Imaging Compendium™, visit NCCN.org/ImagingAUC .

###

About the National Comprehensive Cancer Network

The National Comprehensive Cancer Network® (NCCN®), a not-for-profit alliance of 27 of the world’s leading cancer centers devoted to patient care, research, and education, is dedicated to improving the quality, effectiveness, and efficiency of cancer care so that patients can live better lives. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system. As the arbiter of high-quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers.

The NCCN Member Institutions are: Fred & Pamela Buffett Cancer Center, Omaha, NE; Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; City of Hope Comprehensive Cancer Center, Los Angeles, CA; Dana-Farber/Brigham and Women’s Cancer Center | Massachusetts General Hospital Cancer Center, Boston, MA; Duke Cancer Institute, Durham, NC; Fox Chase Cancer Center, Philadelphia, PA; Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT; Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance, Seattle, WA; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL; Mayo Clinic Cancer Center, Phoenix/Scottsdale, AZ, Jacksonville, FL, and Rochester, MN; Memorial Sloan Kettering Cancer Center, New York, NY; Moffitt Cancer Center, Tampa, FL; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute, Columbus, OH; Roswell Park Cancer Institute, Buffalo, NY; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine, St. Louis, MO; St. Jude Children’s Research Hospital/The University of Tennessee Health Science Center, Memphis, TN; Stanford Cancer Institute, Stanford, CA; University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, AL; UC San Diego Moores Cancer Center, La Jolla, CA; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; University of Colorado Cancer Center, Aurora, CO; University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; The University of Texas MD Anderson Cancer Center, Houston, TX; University of Wisconsin Carbone Cancer Center, Madison, WI; Vanderbilt-Ingram Cancer Center, Nashville, TN; and Yale Cancer Center/Smilow Cancer Hospital, New Haven, CT.

Clinicians, visit NCCN.org . Patients and caregivers, visit NCCN.org/patients . Media, visit NCCN.org/news .

Katie Kiley Brown, NCCN Communications Manager

215.690.0238

brown@nccn.org

Tags:

About Us

The National Comprehensive Cancer Network® (NCCN®), a not-for-profit alliance of 27 of the world’s leading cancer centers devoted to patient care, research, and education, is dedicated to improving the quality, effectiveness, and efficiency of cancer care so that patients can live better lives. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system. As the arbiter of high-quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers.

Subscribe

Quick facts

New NCCN Imaging Appropriate Use Criteria Compendium provides a single access point for all imaging recommendations within the NCCN Guidelines.
Tweet this

Quotes

The launch of the NCCN Imaging AUC furthers our mission to improve the lives of people with cancer. This easy-to-use resource, based on the unbiased, expert opinion of NCCN Guidelines panel members, enhances clinical decision-making and helps patients receive the very best of cancer care possible.
Robert W. Carlson, MD, Chief Executive Officer, NCCN